PLATINIUM, released simultaneously in both Europe and Japan by LivaNova (formerly Sorin Group), will protect patients from avoidable replacement surgeries and the inherent risk of complications.

Please provide your email address to receive an email when new articles are posted on . Among the features of the new European Society of Cardiology guideline on pacing and cardiac resynchronization ...

San Francisco, CA - When a heart-failure patient has a defibrillator-equipped cardiac resynchronization therapy (CRT-D) device, antitachycardia pacing (ATP) is preferable to a shock for the treatment ...

Please provide your email address to receive an email when new articles are posted on . Among patients with nonischemic cardiomyopathy, women were less likely to die or have a ventricular event than ...

ST. PAUL, Minn. St. Jude Medical, Inc. today announced regulatory approval from the Japanese Ministry of Health, Labor and Welfare (MHLW) and the launch of the Fortify(TM) ST implantable cardioverter ...

MINNEAPOLIS - Medtronic, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved an expanded indication for biventricular (BiV) pacing with Medtronic cardiac resynchronization ...

On the heels of a unanimous FDA panel recommendation in March for an expanded indication of Boston Scientific's (Natick, Massachusetts) cardiac resynchronization therapy defibrillators (CRT-Ds), ...

CHICAGO, Nov 14 (Reuters) - Patients with mild to moderate heart failure benefited from an implanted Medtronic Inc device that combines a pacemaker to coordinate pumping with a defibrillator that ...

The major trials that established cardiac resynchronization therapy (CRT) as a treatment for heart failure (HF) with reduced ejection fraction (HFrEF) tended not to include patients who already had ...

The Resynchronization–Defibrillation for Ambulatory Heart Failure Trial (RAFT) showed a greater benefit with respect to mortality at 5 years among patients who received cardiac-resynchronization ...

The U.S. FDA has given its nod to Abbott Laboratories' next-generation Gallant implantable cardioverter defibrillator (ICD) and cardiac resynchronization therapy defibrillator (CRT-D) devices. The ...

Implanted devices that treat cardiac dysfunction in heart failure patients are as successful in "real world" use as they are in controlled clinical trial settings, according to a large new study ...